- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03338998
Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).
A Phase II, Patient- and Investigator-blinded, Randomized, Placebo-controlled Study to Evaluate Efficacy, Safety and Tolerability of BAF312 (Siponimod) in Patients With Stroke Due to Intracerebral Hemorrhage (ICH)
Study Overview
Status
Conditions
Detailed Description
This was the first trial of BAF312 in ICH patients to evaluate if BAF312 had the potential to limit brain inflammation after ICH, and thereby improve neurological outcome for stroke patients when administered in addition to standard of care.
ICH patients meeting study criteria were randomized at 1:1 ratio into either active or placebo group. Patients received an intravenous infusion (i.v.) treatment within 24 hours of an ICH event and were up titrated for 7 days. Following the i.v. treatment, participants received 10 mg BAF312 or placebo in tablet form (taken daily orally) for an additional 7 days. Participants were followed for an additional 76 days after treatment for neurological and safety conditions during three clinic visits.
Recruitment for the trial was put on hold due to the COVID-19 pandemic. Thirty-two patients had been enrolled in the trial and completed the protocol as planned. After seven months of the trial being on hold, an Interim analysis was conducted and reviewed by the Data Monitoring Committee. Novartis terminated the trial due to lack of potential efficacy.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304
- Novartis Investigative Site
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Novartis Investigative Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30303
- Novartis Investigative Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Novartis Investigative Site
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Novartis Investigative Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Novartis Investigative Site
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Novartis Investigative Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104-4283
- Novartis Investigative Site
-
-
Texas
-
Houston, Texas, United States, 77024
- Novartis Investigative Site
-
Houston, Texas, United States, 77030-3900
- Novartis Investigative Site
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
ICH patients eligible for inclusion in this study must fulfill all of the following criteria:
- Male or female patients aged 18 to 85 years (inclusive).
- Written informed consent obtained before any study assessment is performed. If the patient is not able to give the informed consent personally, consent by a relative or legal representative is acceptable.
- Spontaneous, supratentorial intracerebral hemorrhage in cerebral cortex or deep brain structures (putamen, thalamus, caudate, and associated deep white matter tracts) with a volume ≥ 10 mL but ≤ 60 mL (calculated by the ABC/2 method, after Kothari et al 1996) determined by routine clinical MRI or CT.
- Patients with the onset of ICH witnessed and/or last seen healthy no longer than 24 hrs previously.
- Patients with Glasgow Coma Scale (GCS) best motor score no less than 5 (brings hands above clavicle on stimulus to head or neck).
Exclusion Criteria:
ICH patients fulfilling any of the following criteria are not eligible for inclusion in this study:
- Use of other investigational drugs within 5 half-lives of enrollment, or until the expected pharmacodynamic effect has returned to baseline (for biologics), whichever is longer.
- History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes (e.g., fingolimod).
- Current use of concomitant medications with potent CYP2C9/3A4 inhibitory or induction potential.
- Infratentorial (midbrain, pons, medulla, or cerebellum) ICH.
- Candidates for surgical hematoma evacuation or other urgent surgical intervention (i.e., surgical relief of increased intracranial pressure) on initial presentation. If during the treatment period surgical hematoma evacuation or surgical intervention to lower intracranial pressure becomes indicated, the investigational treatment should be stopped.
- Patients with intraventricular hemorrhage (IVH) having a Graeb score of >3 on initial presentation. Patients must not have blood in the 4th ventricle and may only have blood in the 3rd ventricle in the absence of ventricular expansion. Trace or mild hemorrhage in either or both lateral ventricles is permitted. Patients with hydrocephalus determined radiologically on initial presentation are excluded regardless of Graeb score.
Secondary ICH due to:
- aneurysm
- brain tumor
- arteriovenous malformation
- thrombocytopenia, defined as platelet count of <150,000/µl
- known history of coagulopathy
- acute sepsis
- traumatic brain injury (TBI)
- disseminated intravascular coagulation (DIC)
- Prior disability due to other disease compromising mRS evaluation, thereby interfering with the primary outcome, operationally defined as an estimated mRS score (by history) of ≥ 3 before ICH for patients less than or equal to 80 years of age. For ICH patients 81-85 years of age, estimated mRS by history prior to ICH must be less than or equal to 1 (no significant disability despite symptoms).
- Preexisting unstable epilepsy.
- Patients with active systemic bacterial, viral or fungal infections.
Concomitant drug-related exclusion criteria:
- Intravenous immunoglobulin, immunosuppressive and/or chemotherapeutic medications.
- Moderate immunosuppressives (e.g. azathioprine, methotrexate) and/or fingolimod within 2 months prior to randomization.
- Stronger immunosuppressives (e.g. cyclophosphamide, immunosuppressive mAb) within (minimally) 6 months prior to randomization, or longer with long-lasting immunosuppressive medications as determined by the investigator.
Cardiovascular exclusion criteria:
- Cardiac conduction or rhythm disorders including sinus arrest or sino-atrial block, heart rate <50 bpm, sick-sinus syndrome, Mobitz Type II second degree AV block or higher grade AV block, or preexisting atrial fibrillation (either by history or observed at screening).
- PR interval >220 msec. Long QT syndrome or QTcF prolongation >450 msec in males or >470 msec in females on screening electrocardiogram (ECG).
- Patients receiving treatment with QT-prolonging drugs having a long half-life (e.g., amiodarone).
Any of the following abnormal laboratory values prior to randomization:
- White blood cell (WBC) count < 2,000/μl (< 2.0 x 109/L)
- Lymphocyte count < 800/μl (< 0.8 x 109/L)
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
- Patients with any other medically unstable condition or serious laboratory abnormality as determined by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BAF312
Days 1 - 7, IV up titration; days 8 - 14, 10 mg (5 x 2 mg tablets) taken daily orally
|
Solution for intravenous (IV) infusion - 4.5mg/4.5mL
Other Names:
2 mg film-coated tablet
Other Names:
|
Placebo Comparator: Placebo
Days 1 - 7, IV up titration; days 8 - 14, 10 mg (5 x 2 mg tablets) taken daily orally - matching placebo
|
Solution for intravenous (IV) infusion - 0mg/4.5mL
matching placebo
0 mg film-coated tablet matching placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Absolute Perihematoma Edema (aPHE) Volume Measured by Computed Tomography (CT) Scan After Intracerebral Hemorrhage (ICH)
Time Frame: On Day 14 following ICH
|
Following the initial diagnostic CT, repeat CT images were obtained between 24-48 h after the diagnostic scan, and on Day 7 and Day 14 to capture the trajectory of PHE increase and plateau after ICH.
Only non-contrast study CT scans were obtained on Day 7 and Day 14.
The non-contrast scan acquired on each patient at first follow-up (i.e.
24-48 h after the diagnostic scan) served as the baseline for our analysis.
All CT scans were uploaded through a secure server, and edema and hematoma volumes were measured in a semi-automated manner by one Central Reader.
|
On Day 14 following ICH
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma BAF312 Concentrations
Time Frame: Days 1, 8, and 14
|
Blood samples will be collected to assess plasma concentrations.
|
Days 1, 8, and 14
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kevin N. Sheth, MD, Yale University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Intracranial Hemorrhages
- Stroke
- Hemorrhage
- Cerebral Hemorrhage
- Hemorrhagic Stroke
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Immunosuppressive Agents
- Immunologic Factors
- Sphingosine 1 Phosphate Receptor Modulators
- Pharmaceutical Solutions
- Siponimod
Other Study ID Numbers
- CBAF312X2207
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemorrhagic Stroke
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
Royal Holloway UniversityRecruitingStroke | Stroke, Ischemic | Stroke HemorrhagicUnited Kingdom
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
University of MinnesotaNational Heart, Lung, and Blood Institute (NHLBI)CompletedStroke | Stroke, Ischemic | Stroke HemorrhagicUnited States
-
IRCCS Centro San Giovanni di Dio FatebenefratelliAzienda Ospedaliero, Universitaria Pisana; Azienda Ospedaliera Universitaria... and other collaboratorsUnknownStroke, Ischemic | Stroke HemorrhagicItaly
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
Khyber Medical University PeshawarRecruitingStroke | Stroke, Ischemic | Stroke HemorrhagicPakistan
Clinical Trials on BAF312 solution
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Enrolling by invitationHealthy | ObesityUnited States
-
Novartis PharmaceuticalsCompletedRelapsing Remitting Multiple SclerosisHungary, Turkey, Spain, Germany, Canada, Switzerland, United States, Norway, Russian Federation, Italy, Finland, Poland
-
Novartis PharmaceuticalsCompletedHepatic ImpairmentHungary, Russian Federation
-
Novartis PharmaceuticalsTerminatedActive DermatomyositisUnited States, Czechia, Japan
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple SclerosisPoland, Hungary, Turkey, Spain, Germany, United States, Canada, Switzerland, Russian Federation, Norway, Italy, Finland
-
Novartis PharmaceuticalsTerminatedDermatomyositis | PolymyositisHungary, United States, Czechia, Sweden, United Kingdom
-
Novartis PharmaceuticalsTerminatedPolymyositisHungary, Taiwan, United States, Canada, Czechia, Poland
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsCompletedSecondary Progressive Multiple SclerosisChina, Germany, United States, Romania, Italy, Austria, Belgium, Czechia, Spain, Australia, Canada, France, Israel, Switzerland, Japan, Bulgaria, Netherlands, United Kingdom, Estonia, Latvia, Lithuania, Russian Federation, Turkey, Slo... and more
-
Novartis PharmaceuticalsCompletedMultiple Sclerosis | Relapsing Multiple Sclerosis | Advancing Multiple SclerosisUnited States, Puerto Rico